CALCITRIOL INJECTION SOLUTION

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

CALCITRIOL

Disponible depuis:

FRESENIUS KABI CANADA LTD

Code ATC:

A11CC04

DCI (Dénomination commune internationale):

CALCITRIOL

Dosage:

1MCG

forme pharmaceutique:

SOLUTION

Composition:

CALCITRIOL 1MCG

Mode d'administration:

INTRAVENOUS

Unités en paquet:

1ML

Type d'ordonnance:

Prescription

Domaine thérapeutique:

VITAMIN D

Descriptif du produit:

Active ingredient group (AIG) number: 0113628002; AHFS:

Statut de autorisation:

CANCELLED POST MARKET

Date de l'autorisation:

2023-03-10

Résumé des caractéristiques du produit

PRODUCT MONOGRAPH
PR
CALCITRIOL INJECTION
1 MCG/ML AND 2 MCG/ML
Vitamin D
3
metabolite
FRESENIUS KABI CANADA LTD.
165 Galaxy Blvd, Suite 100
Date of Revision:
Toronto, ON, M9W 0C8
November 16, 2017
Submission Control No.: 199558
Calcitriol Injection – Product Monograph
_ _
Page 2 of 23
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
3
WARNINGS AND PRECAUTIONS
...............................................................................................
4
ADVERSE REACTIONS
.................................................................................................................
6
DRUG INTERACTIONS
.................................................................................................................
8
DOSAGE AND ADMINISTRATION
.............................................................................................
9
OVERDOSAGE
.............................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
10
STORAGE AND STABILITY
.......................................................................................................
12
SPECIAL HANDLING INSTRUCTIONS
....................................................................................
12
DOSAGE FORMS, COMPOSITION AND
PACKAGING...........................................................
12
PART II: SCIENTIFIC INFORMATION
...................................................................................
13
PHARMACEUTICAL INFORMATION
......